The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.
REGiMMUNE and Kiji Therapeutics to Merge
The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.